by Rod Raynovich | Feb 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Rally Underway The NASDAQ market recovered from near 1% losses today caused by the Cisco(CSCO) earnings report and guidance. The NASDAQ is currently flat to slightly down at 2785 recovering from the 2760 level. Expectations that Egypt’s President...
by Rod Raynovich | Feb 9, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Life Sciences Market Remains Strong while M&A Provides Support As we enter the peak earnings season for many tools and device companies, initial reports would indicate that investor expectations are higher and stocks could have a bit of profit taking. Genomic...
by Rod Raynovich | Feb 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Healthcare and Biotechnology stocks are underperforming the S&P YTD-Medical Devices and Equipment are a bright spot up over 4% YTD. The Q4 2010 momentum in biotech stocks has ebbed in 2011 as the broad market rally continues. The S&P is up 5% YTD while the...
by Rod Raynovich | Jan 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX,...
by Rod Raynovich | Jan 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down...
by Rod Raynovich | Jan 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the...
by Rod Raynovich | Jan 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Stay the Course for Now We will review our holdngs next week and rebalance if necessary. Overall it has been a good week with biotech indices up about 2%. Late January is always a good time for a correction but for now it is “don’t fight the FED,...
by Rod Raynovich | Jan 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics announced today that it signed a definitive merger agreement with IDEX Corp.(IEX) for $1.35 net cash to the seller subject to adjustment as provided in the merger agreement. The $1.35 price represents about a 58% premium over recent trading and a 69%...
by Rod Raynovich | Jan 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
We will be attending the JPMorgan Healthcare Conference in San Francisco next week looking for new ideas. Healthcare overall has been a laggard (up 1.87% vs 11.47% S&P for one year period) but subsectors such as diagnostics, tools, large cap drugs and selected...
by Rod Raynovich | Jan 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Diagnostics and Tools 2010 Original Price Price % Ret Recomm YrEnd’10 Abaxis ABAX 2/2/09 15 26.85 79 CardioV.Sys. CSII 11/5/10 7.15 11.66 63 Celera CRA 3/28/10 7 6.3 -10 Exact Sci EXAS 12/10/10 5.6 5.98 6.8 GenProbe GPRO 2/2/09 45 58.35 29.7 Illumina ILMN 2/2/09...
